The incidence of factor VIII and factor IX inhibitors in the hemophilia population of the UK and their effect on subsequent mortality, 1977–99
- 1 July 2004
- journal article
- research article
- Published by Elsevier BV in Journal of Thrombosis and Haemostasis
- Vol. 2 (7), 1047-1054
- https://doi.org/10.1046/j.1538-7836.2004.00710.x
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- Cost of care and quality of life for patients with hemophilia complicated by inhibitors: the COCIS Study GroupBlood, 2003
- Factors predictive of death among HIV‐uninfected persons with haemophilia and other congenital coagulation disordersHaemophilia, 2002
- Mortality before and after HIV infection in the complete UK population of haemophiliacsNature, 1995
- The incidence of factor VIII inhibitors in the United Kingdom, 1990‐93British Journal of Haematology, 1995
- Frequency of inhibitor development in haemophiliacs treated with low-purity factor VIIIThe Lancet, 1993
- Incidence of development of factor VIII and factor IX inhibitors in haemophiliacsThe Lancet, 1992
- Viral safety and inhibitor development associated with monoclonal antibody-purified F VIII CAnnals of Hematology, 1991
- Haemophiliacs with factor VIII inhibitors in Finland: prevalence, incidence and outcomeBritish Journal of Haematology, 1990
- Disappearance of inhibitor to factor VIII in HIV‐infected hemophiliacs with progression to AIDS or severe ARCTransfusion, 1989
- The Effect of Activated Prothrombin-Complex Concentrate (FEIBA) on Joint and Muscle Bleeding in Patients with Hemophilia A and Antibodies to Factor VIIINew England Journal of Medicine, 1981